Lab21 acquires Microgen Bioproducts

Lab21 Ltd, a specialist in personalised medicine and clinical diagnostics, has acquired Microgen Bioproducts Ltd a UK company specialising in the development, manufacture and sale of diagnostic tests to identify diseases and organisms which pose a threat to health. The company’s expertise in microbiological assay development and commercialisation complements Lab21’s extensive diagnostics portfolio particularly in the infectious disease market. This transaction provides further expansion of Lab21’s distribution channel in key territories including the US, UK, Europe and Asia.

Graham Mullis, CEO of Lab21, said: “Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21’s commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011.”

Dan Deery, Managing Director of Microgen Bioproducts, added: “Lab21 has built a strong reputation, with a global reach and innovative products. We are delighted to join forceswith them.”